Sweden
· Delayed Price · Currency is SEK CALTX Statistics
Total Valuation
Calliditas Therapeutics AB has a market cap or net worth of SEK 11.17 billion. The enterprise value is 11.39 billion.
| Market Cap | 11.17B |
| Enterprise Value | 11.39B |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Calliditas Therapeutics AB has 54.03 million shares outstanding. The number of shares has increased by 0.40% in one year.
| Shares Outstanding | 54.03M |
| Shares Change (YoY) | +0.40% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 12.72% |
| Owned by Institutions (%) | 24.61% |
| Float | 32.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 15.64 |
| PS Ratio | 6.93 |
| PB Ratio | 104.59 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -23.70 |
| EV / Sales | 7.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -44.18 |
Financial Position
The company has a current ratio of 2.69, with a Debt / Equity ratio of 944.17.
| Current Ratio | 2.69 |
| Quick Ratio | 2.37 |
| Debt / Equity | 944.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.91 |
| Interest Coverage | -3.55 |
Financial Efficiency
Return on equity (ROE) is -157.20% and return on invested capital (ROIC) is -19.31%.
| Return on Equity (ROE) | -157.20% |
| Return on Assets (ROA) | -13.41% |
| Return on Capital (ROIC) | -19.31% |
| Revenue Per Employee | 7.21M |
| Profits Per Employee | -2.16M |
| Employee Count | 222 |
| Asset Turnover | 0.93 |
| Inventory Turnover | 3.62 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +122.01% in the last 52 weeks. The beta is 1.48, so Calliditas Therapeutics AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | +122.01% |
| 50-Day Moving Average | 206.22 |
| 200-Day Moving Average | 142.70 |
| Relative Strength Index (RSI) | 65.41 |
| Average Volume (20 Days) | 156,557 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Calliditas Therapeutics AB had revenue of SEK 1.60 billion and -480.36 million in losses. Loss per share was -8.95.
| Revenue | 1.60B |
| Gross Profit | 1.50B |
| Operating Income | -370.67M |
| Pretax Income | -468.32M |
| Net Income | -480.36M |
| EBITDA | -365.37M |
| EBIT | -370.67M |
| Loss Per Share | -8.95 |
Balance Sheet
The company has 797.28 million in cash and 1.01 billion in debt, giving a net cash position of -210.99 million or -3.90 per share.
| Cash & Cash Equivalents | 797.28M |
| Total Debt | 1.01B |
| Net Cash | -210.99M |
| Net Cash Per Share | -3.90 |
| Equity (Book Value) | 106.79M |
| Book Value Per Share | 1.98 |
| Working Capital | 724.69M |
Cash Flow
In the last 12 months, operating cash flow was -244.93 million and capital expenditures -12.79 million, giving a free cash flow of -257.72 million.
| Operating Cash Flow | -244.93M |
| Capital Expenditures | -12.79M |
| Free Cash Flow | -257.72M |
| FCF Per Share | -4.77 |
Margins
Gross margin is 93.46%, with operating and profit margins of -23.15% and -30.00%.
| Gross Margin | 93.46% |
| Operating Margin | -23.15% |
| Pretax Margin | -29.24% |
| Profit Margin | -30.00% |
| EBITDA Margin | -22.82% |
| EBIT Margin | -23.15% |
| FCF Margin | -16.09% |
Dividends & Yields
Calliditas Therapeutics AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.40% |
| Shareholder Yield | -0.40% |
| Earnings Yield | -4.33% |
| FCF Yield | -2.31% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |